v3.26.1
Fair value measurement (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis
The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2026 and December 31, 2025:
Total carrying
 value at
 June 30, 2026
Quoted prices in active
markets (Level 1)
Significant other
observable
Inputs (Level 2)
Significant
unobservable
Inputs (Level 3)
Investments in marketable securities$26,443 $26,443 $— $— 
Derivative assets29,326 — 29,326 — 
Derivative liabilities66,954 — 66,954 — 
Contingent consideration liabilities47,412 — — 47,412 
Total carrying
value at December 31, 2025
Quoted prices in active
markets (Level 1)
Significant other
observable
Inputs (Level 2)
Significant
unobservable
Inputs (Level 3)
Investments in marketable securities$32,830 $32,830 $— $— 
Derivative assets31,879 — 31,879 — 
Derivative liabilities134,254 — 134,254 — 
Contingent consideration liabilities50,218 — — 50,218 
Schedule of Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis
The following table provides information regarding changes in our contingent consideration liabilities for the six months ended June 30, 2026:
Contingent consideration
Balance – December 31, 2025
$50,218 
Payments(107)
Revaluations(2,699)
Balance – June 30, 2026 (1)
$47,412 
(1)    As of June 30, 2026, the liability consisted largely of the estimated contingent consideration associated with our 2023 acquisition of Palette Life Sciences AB ("Palette"). Timing of payment is contingent on the resolution of the legal matters discussed in Note 14.